JP5999703B2 - ＨＬＡ−ＤＲ１拘束性Ｔａｘ特異的ＣＤ４＋Ｔ細胞エピトープ - Google Patents

ＨＬＡ−ＤＲ１拘束性Ｔａｘ特異的ＣＤ４＋Ｔ細胞エピトープ Download PDF

Info

Publication number
JP5999703B2
JP5999703B2 JP2013002127A JP2013002127A JP5999703B2 JP 5999703 B2 JP5999703 B2 JP 5999703B2 JP 2013002127 A JP2013002127 A JP 2013002127A JP 2013002127 A JP2013002127 A JP 2013002127A JP 5999703 B2 JP5999703 B2 JP 5999703B2
Authority
JP
Japan
Prior art keywords
amino acid
acid sequence
htlv
specific
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2013002127A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014133712A (ja
JP2014133712A5 (enExample
Inventor
洋太郎 玉井
洋太郎 玉井
温彦 長谷川
温彦 長谷川
真理 神奈木
真理 神奈木
隆二 田野崎
隆二 田野崎
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tokyo Medical and Dental University
Original Assignee
Tokyo Medical and Dental University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tokyo Medical and Dental University filed Critical Tokyo Medical and Dental University
Priority to JP2013002127A priority Critical patent/JP5999703B2/ja
Priority to PCT/JP2014/000053 priority patent/WO2014109289A1/ja
Publication of JP2014133712A publication Critical patent/JP2014133712A/ja
Publication of JP2014133712A5 publication Critical patent/JP2014133712A5/ja
Application granted granted Critical
Publication of JP5999703B2 publication Critical patent/JP5999703B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70514—CD4
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G01N33/56988—HIV or HTLV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/61—Fusion polypeptide containing an enzyme fusion for detection (lacZ, luciferase)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/14011—Deltaretrovirus, e.g. bovine leukeamia virus
    • C12N2740/14034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus, feline leukaemia virus, human T-cell leukaemia-lymphoma virus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • AIDS & HIV (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
JP2013002127A 2013-01-09 2013-01-09 ＨＬＡ−ＤＲ１拘束性Ｔａｘ特異的ＣＤ４＋Ｔ細胞エピトープ Expired - Fee Related JP5999703B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2013002127A JP5999703B2 (ja) 2013-01-09 2013-01-09 ＨＬＡ−ＤＲ１拘束性Ｔａｘ特異的ＣＤ４＋Ｔ細胞エピトープ
PCT/JP2014/000053 WO2014109289A1 (ja) 2013-01-09 2014-01-09 ＨＬＡ－ＤＲ１拘束性Ｔａｘ特異的ＣＤ４＋Ｔ細胞エピトープ

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2013002127A JP5999703B2 (ja) 2013-01-09 2013-01-09 ＨＬＡ−ＤＲ１拘束性Ｔａｘ特異的ＣＤ４＋Ｔ細胞エピトープ

Publications (3)

Publication Number Publication Date
JP2014133712A JP2014133712A (ja) 2014-07-24
JP2014133712A5 JP2014133712A5 (enExample) 2015-11-05
JP5999703B2 true JP5999703B2 (ja) 2016-09-28

Family

ID=51166939

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013002127A Expired - Fee Related JP5999703B2 (ja) 2013-01-09 2013-01-09 ＨＬＡ−ＤＲ１拘束性Ｔａｘ特異的ＣＤ４＋Ｔ細胞エピトープ

Country Status (2)

Country Link
JP (1) JP5999703B2 (enExample)
WO (1) WO2014109289A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018116074A1 (en) * 2016-12-19 2018-06-28 Kabiri Mona Chimeric peptides against htlv-1
JP7411988B2 (ja) * 2019-11-13 2024-01-12 文彦 松田 Ｈａｍ／ｔｓｐ発症リスク判定方法
WO2021167094A1 (ja) 2020-02-20 2021-08-26 陽子 末廣 末梢血原料の採取／凍結融解工程における単球純化法
JPWO2023163094A1 (enExample) * 2022-02-25 2023-08-31
KR20260074976A (ko) * 2023-09-19 2026-05-27 리제너론 파마슈티칼스 인코포레이티드 바이러스 펩티드 및 이의 용도

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5063150A (en) * 1984-09-19 1991-11-05 The Regents Of The University Of California Retroviral polypeptides associated with human cellular transformation
US5717058A (en) * 1993-02-23 1998-02-10 Somatogen, Inc. Peptide inhibitors of tax-dependent transcription
US5420244A (en) * 1993-08-06 1995-05-30 The United States Of America As Represented By The Department Of Health And Human Services Methods and compositions for diagnosing HTLV-I associated myelopathy and adult T-cell leukemia
JPH09188696A (ja) * 1996-08-01 1997-07-22 Seishi Nokihara ヒト成人白血病ワクチン用の合成ペプチド
CA2323632A1 (en) * 1998-03-13 1999-09-16 Epimmune Inc. Hla-binding peptides and their uses
WO2004092373A1 (ja) * 2003-04-16 2004-10-28 Japan Science And Technology Agency Ｈｔｌｖ－ｉ特異的ｃｔｌ誘導活性ペプチド
WO2010009465A2 (en) * 2008-07-18 2010-01-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Htlv-ii vector and methods of use

Also Published As

Publication number Publication date
WO2014109289A9 (ja) 2014-12-24
JP2014133712A (ja) 2014-07-24
WO2014109289A1 (ja) 2014-07-17

Similar Documents

Publication Publication Date Title
US11707512B2 (en) Cancer vaccine composition
JP5484734B2 (ja) Ｈｌａ−ａ＊１１０１拘束性ｗｔ１ペプチド、およびそれを含む医薬組成物
DK2186889T3 (en) CDCA1 PEPTID AND PHARMACEUTICAL COMPOSITION, INCLUDING THIS
CN111032686B (zh) 血液恶性肿瘤的治疗
Kawashima et al. Identification of GP100‐derived, melanoma‐specific cytotoxic T‐lymphocyte epitopes restricted by HLA‐A3 supertype molecules by primary in vitro immunization with peptide‐pulsed dendritic cells
KR20020026461A (ko) 제2형 ｈｌａ 분자에 의해 제시되는 ｍａｇｅ-ａ1 펩티드
WO2014109289A1 (ja) ＨＬＡ－ＤＲ１拘束性Ｔａｘ特異的ＣＤ４＋Ｔ細胞エピトープ
JPWO2009022652A1 (ja) ＨＬＡ−Ａ３スーパータイプアレル陽性癌患者に対する癌ワクチン療法に有用なＬｃｋ由来ペプチド
EP1616950B1 (en) Peptide having htlv-1-specific ctl-inducing activity
JP5176099B2 (ja) ＨＬＡ−Ａ１１拘束性Ｔａｘ抗腫瘍エピトープ
CN121398839A (zh) Timp3来源的teipp新抗原及其用途
JP2025508970A (ja) Ｈｌａ－ａ＊０２：０１制限ヒト前立腺酸性ホスファターゼ（ｐａｐ）エピトープとの反応性を示すヒトｔ細胞受容体対
JP2024123281A (ja) ＳＡＲＳ－ＣｏＶ－２由来のＴ細胞エピトープペプチド
CN121398838A (zh) Rcn1来源的teipp新抗原及其用途
HK1143552B (en) Cancer vaccine composition
HK1143552A (en) Cancer vaccine composition
HK1261028B (en) Cancer vaccine composition

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150910

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150910

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160613

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160802

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20160822

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20160824

R150 Certificate of patent or registration of utility model

Ref document number: 5999703

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees